Denileukin diftitox for the treatment of cutaneous T-cell lymphoma

Bibliography

• Kashani-Sabet M, McMillan A, Zackheim HS. A modified staging classification for cutaneous T-cell lymphoma. J Am Acad Dermatol 2001;45:700-6
   PubMed Web of Science ®Google Scholar
• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous T-cell lymphomas. Blood 2005;105:3768-85
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Non-Hodgkin's lymphomas v.1.2011. Fort Washington, PA: National Comprehensive Cancer Network. 2011. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp [Accessed 15 December 2013]
   Google Scholar
• Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases. Blood 2009;113:5064-73
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Olsen EA, Duvic M, et al. Review of the treatment of mycosis fungoides and Sezary syndrome: a stage-based approach. J Natl Compr Canc Netw 2008;6(4):436-42
   PubMedGoogle Scholar
• Dummer R, Dreyling M. Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008;19(Suppl 2):72-6
   Web of Science ®Google Scholar
• Trautinger F, Knobler R, Willemze R, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 2006;42(8):1014-30
   PubMed Web of Science ®Google Scholar
• Kim YH, Liu HL, Mraz-Gernhard S, et al. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139(7):857-66
   PubMedGoogle Scholar
• Zackheim HS, Amin S, Kashani-Sabet M, et al. Prognosis in cutaneous T-cell lymphoma by skin stage: long term survival in 489 patients. J Am Acad Dermatol 1999;40(3):418-25
   Google Scholar
• Van Doorn R, Van Haselen CW, van Voorst Vader PC, et al. Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. Arch Dermatol 2000;136(4):504-10
   PubMedGoogle Scholar
• Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sezary syndrome. Blood 2009;114:4337-53
   PubMed Web of Science ®Google Scholar
• Li JY, Horwitz S, Moskowitz A, et al. Management of cutaneous T cell lymphoma: new and emerging targets and treatment options. Cancer Manag Res 2012;4:75-89
   PubMedGoogle Scholar
• Prince HM, Duvic M, Martin A, et al. Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. J Clin Oncol 2010;28:1870-7
   PubMed Web of Science ®Google Scholar
• Zain J, O'Connor OA. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs 2010;28(Suppl 1):S58-78
   PubMed Web of Science ®Google Scholar
• Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(21):3109-15
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012;119(18):4115-22
   PubMed Web of Science ®Google Scholar
• Querfeld C, Rosen ST, Guitart J, et al. Results of an open-label multicenter phase II trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. Blood 2014;123(8):1159-66
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortexomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25(27):4293-7
   PubMed Web of Science ®Google Scholar
• Marchi E, Alinari L, Tani M, et al. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients. Cancer 2005;104(11):2437-41
   PubMedGoogle Scholar
• Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer 2003;98(5):993-1001
   PubMed Web of Science ®Google Scholar
• Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006;7(1):51-8
   PubMedGoogle Scholar
• Lundin J, Hagberg H, Repp R, et al. Phase II study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101(11):4267-72
   PubMed Web of Science ®Google Scholar
• Querfeld C, Mehta N, Rosen ST, et al. Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H.Lurie Comprehensive Cancer Center. Leuk Lymphoma 2009;50(12):1969-76
   PubMed Web of Science ®Google Scholar
• Available from: http://www.campath.com/ [Last accessed 4 February 2014]
   Google Scholar
• Whittaker S, Dummer R, Scarisbrick J, et al. Phase 3 study of brentuximab vedotin versus physician's choice in patients with CD30-positive cutaneous T-cell lymphoma. The ALCANZA study. Poster presented at the 6th Annual T-cell Lymphoma Forum; 23 – 25 January 2014; San Francisco, CA
   Google Scholar
• Kim YH, Girardi M, Duvic M, et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010;63(6):975-83
   PubMed Web of Science ®Google Scholar
• Duarte RF, Canals C, Onida E, et al. Allogeneic haematopoetic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010;28(29):4492-9
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Minami Y. The IL-2/IL-2 receptor system: a current overview. Cell 1993;73:5-8
   PubMed Web of Science ®Google Scholar
• Nakase K, Kita K, Nasu K, et al. Differential expression of interleukin-2 receptors (alpha and beta chain) in mature lymphoid neoplasms. Am J Hematol 1994;46:179-83
   PubMed Web of Science ®Google Scholar
• Nichols J, Foss F, Kuzel TM, et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 expressing malignancies. Eur J Cancer 1997;33:S34-6
   PubMed Web of Science ®Google Scholar
• Re GG, Waters C, Poisson L, et al. Interleukin 2 (IL-2) receptor expression and sensitivity to diphtheria fusion toxin DAB389IL-2 in cultured hematopoetic cells. Cancer Res 1996;56:2590-6
   PubMed Web of Science ®Google Scholar
• Waters CA, Schimke PA, Snider CE, et al. Interleukin 2 receptor-targeted cytotoxicity: receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur J Immunol 1990;20:785-91
   PubMed Web of Science ®Google Scholar
• Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of Deniluekin Diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88
   PubMed Web of Science ®Google Scholar
• Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with deniluekin diftitox: results from 3 phase III studies. Clin Lymphoma Myeloma Leuk 2013;13(4):377-84
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Meneghetti C, Rosenblum M, et al. Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 1992;79:2547-54
   PubMed Web of Science ®Google Scholar
• LeMaistre CF, Saleh MN, Kuzel TM, et al. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expression the receptor for interleukin-2. Blood 1998;91:399-405
   PubMed Web of Science ®Google Scholar
• Saleh MN, LeMaistre CF, Kuzel TM, et al. Antitumour activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998;39(1):63-73
   Google Scholar
• Duvic M, Cather J, Maize J, et al. DAB389IL-2 diphtheria fusion toxin produces clinical responses in tumour stage cutaneous T cell lymphoma. Am J Hematol 1998;58:87-90
   PubMed Web of Science ®Google Scholar
• Steven SR, Ke MS, Mark J, et al. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: the severity-weighted assessment tool (SWAT). Arch Dermatol 2002;138:42-8
   Google Scholar
• Prince HM, Duvic M, Martin M, et al. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sezary syndrome receiving placebo. J Am Acad Dermatol 2012;67:867-75
   Google Scholar
• Horwitz SM. Novel therapies for cutaneous T-cell lymphomas. Clin Lymphoma Myeloma 2008;8(Suppl 5):S187-92
   Google Scholar
• Duvic M, Martin AG, Olsen EA, et al. Efficacy and safety of deileukin diftitox in patients with relapsed cutaneous T-cell lymphoma. Leuk Lymphoma 2013;54(3):514-19
   PubMed Web of Science ®Google Scholar
• Prince HM, Martin AG, Olsen EA, et al. Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sezary syndrome. Leuk Lymphoma 2013;54(1):69-75
   PubMed Web of Science ®Google Scholar
• Ghori F, Polder KD, Pinter-Brown LC, et al. Thyrotoxicosis after denileukin diftitox therapy in patients with mycosis fungoides. J Clin Endocrinol Metab 2006;91:2205-8
   Google Scholar
• Ruddle JB, Harper CA, Honemann D, et al. A denileukin diftitox (Ontak) associated retinopathy? Br J Ophthalmol 2006;90:1070-1
   PubMed Web of Science ®Google Scholar
• Park M, Liu GT, Piltz-Seymour J, et al. Vision loss following denileukin diftitoc treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma 2007;48(4):808-11
   PubMed Web of Science ®Google Scholar
• Ruddle JB, Prince HM. Denileukin diftitox and vision loss. Leuk Lymphoma 2007;48(4):655-6
   PubMed Web of Science ®Google Scholar
• Wong BY, Gregory SA, Dang NH. Denileukin diftitox as novel targeted therapy for lymphoid malignancies. Cancer Invest 2007;25:495-1
   PubMed Web of Science ®Google Scholar
• Manoukian M, Hagermeister F. Denileukin diftitox: a novel immunotoxin. Expert Opin Biol Ther 2009;9(11):1445-51
   PubMed Web of Science ®Google Scholar
• Turturro F. Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther 2007;7(1):11-17
   PubMed Web of Science ®Google Scholar
• Ontak [package insert]. Eisai Medical Research, Inc; Woodcliff: Lake, NJ; 2011
   Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: may 28, 2009 (v4.03: June 14, 2010). Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf [Last accessed 4 February 2014]
   Google Scholar
• A clinical study to demonstrate safety and efficacy of E7777 (Denileukin Diftitox) in persistent or recurrent cutaneous T-cell lymphoma. Woodcliff Lacke, NJ: Eisai Medical Research, Inc. 2013. Available from: http://clinicaltrials.gov/show/NCT01871727 [Last accessed 3 April 2014]
   Google Scholar